Susan Morrison - 30 May 2025 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Reporting relationship: EVP & Chief Admin. Officer
Issuer ticker: TNDM
Reported as of: 30 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 05 Jun 2025, 17:25:47 UTC
Prior SEC filing: 19 May 2025
Next SEC filing: 19 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Rachel Malina, Attorney-in-Fact for Susan M. Morrison

Key filing fact

Susan Morrison filed Form 4 for TANDEM DIABETES CARE INC (TNDM) on 05 Jun 2025.

Key facts

This page summarizes Susan Morrison's Form 4 filing for TANDEM DIABETES CARE INC (TNDM).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 05 Jun 2025, 17:25.

Change

Previous filing in this sequence was filed on 19 May 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001582970 Primary reporting owner

Morrison Susan

Relationship: EVP & Chief Admin. Officer
Address: 12400 HIGH BLUFF DRIVE, SAN DIEGO
Signature: /s/ Rachel Malina, Attorney-in-Fact for Susan M. Morrison
Signature date: 05 Jun 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

TNDM holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 37,206
Date: 30 May 2025
Ownership: Direct

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TNDM transaction Derivative

Performance Stock Unit

Award

Transaction value: $0
Shares: +20,768
Change %
Price: $0.000000
Shares after: 20,768
Date: 30 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,768
Exercise price
Footnotes: F1, F2

TNDM transaction Derivative

Restricted Stock Unit

Award

Transaction value: $0
Shares: +20,768
Change %
Price: $0.000000
Shares after: 20,768
Date: 30 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 20,768
Exercise price
Footnotes: F1, F3, F4

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 4 footnotes

Footnote F1

Awarded on May 30, 2025 pursuant to the Tandem Diabetes Care, Inc. 2023 Long-Term Incentive Plan, as amended, and agreements related thereto (the 2023 Plan).

Footnote F2

Each performance stock unit (PSU) represents a contingent right to receive one share of Tandem Diabetes Care, Inc. (the Company) common stock based upon the achievement of certain pre-defined performance metrics as of December 31, 2027 (the Measurement Date). The number of shares issued may range from 0% to 200% of the amount specified above, based upon (i) Company's actual performance relative to the pre-defined performance metrics, and (ii) subject to the awardee's continuing service through the Measurement Date. If minimum performance metrics are not met, no PSUs will vest.

Footnote F3

Each restricted stock unit (RSU) represents a contingent right to receive either one share of common stock of the Issuer or cash in lieu thereof, at the Issuer's discretion, in accordance with the terms of the 2023 Plan.

Footnote F4

RSU vest as to thirty-three percent (33%) of the total number of shares subject to the RSU on 5/15/2026, and the remaining shares shall vest in eight (8) equal quarterly installments thereafter.